Exhibit 99.1 Acasti Announces Year-End 2024 Financial Results, Provides Business Update • Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 • Projected Cash Runway into Second Calendar Quarter 2026 Princeton, NJ, June 21, 2024 (GLOBE NEWSWIRE)-- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet me ...